Genomic alterations and outcomes with VEGF-targeted therapy in patients with clear cell renal cell carcinoma

M. I. Carlo, B. Manley, S. Patil, K. M. Woo, D. T. Coskey, A. Redzematovic, M. Arcila, M. Ladanyi, W. Lee, Y. B. Chen, C. H. Lee, D. R. Feldman, A. A. Hakimi, R. J. Motzer, J. J. Hsieh, M. H. Voss

Research output: Contribution to journalArticlepeer-review

30 Scopus citations


Background: Mutations in VHL, PBRM1, SETD2, BAP1, and KDM5C are common in clear cell renal cell carcinoma (ccRCC), and presence of certain mutations has been associated with outcomes in patients with non-metastatic disease. Limited information is available regarding the correlation between genomic alterations and outcomes in patients with metastatic disease, including response to VEGF-targeted therapy. Objective: To explore correlations between mutational profiles and cancer-specific outcomes, including response to standard VEGF-targeted agents, in patients with metastatic cc RCC. Methods: A retrospective review of 105 patients with metastatic ccRCC who had received systemic therapy and had targeted next-generation sequencing of tumors was conducted. Genomic alterations were correlated to outcomes, including overall survival and time to treatment failure to VEGF-targeted therapy. Results: The most frequent mutations were detected in VHL (83%), PBRM1 (51%), SETD2 (35%), BAP1 (24%), KDM5C (16%), and TERT (14%). Time to treatment failure with VEGF-targeted therapy differed significantly by PBRM1 mutation status (p = 0.01, median 12.0 months for MT versus 6.9 months for WT) and BAP1 mutation status (p = 0.01, median 6.4 months for MT versus 11.0 months for WT). Shorter overall survival was associated with TERT mutations (p = 0.03, median 29.6 months for MT versus 52.6 months for WT) or BAP1 mutations (p = 0.02, median 28.7 months for MT versus not reached for WT). Conclusions: Genomic alterations in ccRCC tumors have prognostic implications in patients with metastatic disease. BAP1 and TERT promoter mutations may be present in higher frequency than previously thought, and based on this data, deserve further study for their association with poor prognosis.

Original languageEnglish
Pages (from-to)49-56
Number of pages8
JournalKidney Cancer
Issue number1
StatePublished - 2017


  • Clear cell renal cell carcinoma
  • Genomics
  • Prognosis
  • VEGF-targeted therapy


Dive into the research topics of 'Genomic alterations and outcomes with VEGF-targeted therapy in patients with clear cell renal cell carcinoma'. Together they form a unique fingerprint.

Cite this